Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults

被引:27
|
作者
Paternico, Donata [1 ]
Galluzzi, Samantha [1 ]
Drago, Valeria [1 ]
Bocchio-Chiavetto, Luisella [2 ]
Zanardini, Roberta [2 ]
Pedrini, Laura [3 ]
Baronio, Manuela [4 ]
Amicucci, Giovanni [4 ]
Frisoni, Giovanni B. [1 ]
机构
[1] IRCCS San Giovanni di Dio Fatebenefratelli, LENITEM Lab Epidemiol Neuroimaging & Telemed, Brescia, Italy
[2] IRCCS San Giovanni di Dio Fatebenefratelli, Neuropsychopharmacol Unit, Brescia, Italy
[3] IRCCS San Giovanni di Dio Fatebenefratelli, Psychiat Unit, Brescia, Italy
[4] S Orsola Fatebenefratelli Hosp, Anesthesiol Serv, Brescia, Italy
关键词
Cerebrospinal fluid; Biomarkers; Alzheimer's disease; Age; Apolipoprotein E; Healthy adult; RISK-FACTORS; TAU; BIOMARKERS; AGE; DECLINE; ESTABLISHMENT; POPULATION; IMPAIRMENT; DIAGNOSIS; DEMENTIA;
D O I
10.1016/j.jalz.2011.10.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Low amyloid beta(42) (A beta(42)) and high total tau and phosphorylated tau (p-tau) concentrations in the cerebrospinal fluid (CSF) are biomarkers of Alzheimer's disease (AD), reflecting brain deposition of amyloid plaques and tangles. Age and apolipoprotein E allele E4 are two strong risk factors for AD, but few data are still available on their effect on CSF markers in normal aging. Objective: To study the effect of age on CSF A beta(42), total tau, and p-tau levels in a well-characterized group of cognitively normal subjects. Methods: CSF A beta(42) levels of 81 subjects (27% female, 53 +/- 15.3 years, range: 21-88) were determined with sandwich enzyme-linked immunosorbent assay; of these, total tau and p-tau levels were measured in 61 (75%) and 42 (52%) cases, respectively. A linear regression analysis between age and CSF markers was carried out on the whole sample and separately in apolipoprotein E allele epsilon 4 carriers and noncarriers. Results: The median levels of all markers were significantly different between young (<65 years) and old (>= 65 years) subjects (A beta(42): P = .03; tau: P = .02; p-tau: P = .002; tau/A beta(42): P = .004; p-tau/A beta(42): P = .03). The association of marker levels with age was confirmed in linear regression models, where a positive relationship with age was observed for total tau (B = 2.3; 95% confidence interval [CI]: 0.89 to 3.7; P = .002), p-tau (B = 0.5; 95% CI: 0.1 to 0.9; P = .02), and tau/A beta(42) ratio (B = 0.006; 95% CI: 0.002 to 0.01; P = .002). No subjects showed abnormal tau, whereas 19% showed abnormal CSF A beta(42) concentrations. Conclusion: In cognitively normal subjects, the concentrations of CSF biomarkers of AD are associated with age. Further longitudinal studies could clarify whether A beta(42) low levels represent a preclinical AD biomarker. (C) 2012 The Alzheimer's Association. All rights reserved.
引用
收藏
页码:520 / 527
页数:8
相关论文
共 50 条
  • [21] Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia
    Oboudiyat, Carly
    Gefen, Tamar
    Varelas, Eleni
    Weintraub, Sandra
    Rogalski, Emily
    Bigio, Eileen H.
    Mesulam, M. -Marsel
    ALZHEIMERS & DEMENTIA, 2017, 13 (05) : 598 - 601
  • [22] Dimethylarginines, Homocysteine Metabolism, and Cerebrospinal Fluid Markers for Alzheimer's Disease
    Arlt, Soenke
    Schwedhelm, Edzard
    Koelsch, Heike
    Jahn, Holger
    Linnebank, Michael
    Smulders, Yvo
    Jessen, Frank
    Boeger, Rainer H.
    Popp, Julius
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 31 (04) : 751 - 758
  • [23] MicroRNAs in Plasma and Cerebrospinal Fluid as Potential Markers for Alzheimer's Disease
    Kiko, Takehiro
    Nakagawa, Kiyotaka
    Tsuduki, Tsuyoshi
    Furukawa, Katsutoshi
    Arai, Hiroyuki
    Miyazawa, Teruo
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (02) : 253 - 259
  • [24] Cerebrospinal Fluid Inflammatory Markers in Alzheimer's Disease: Influence of Comorbidities
    Wang, Ying
    Emre, Ceren
    Gyllenhammar-Schill, Helena
    Fjellman, Karin
    Eyjolfsdottir, Helga
    Eriksdotter, Maria
    Schultzberg, Marianne
    Hjorth, Erik
    CURRENT ALZHEIMER RESEARCH, 2021, 18 (02) : 157 - 170
  • [25] Cerebrospinal fluid markers of neurodegenerative disorders with emphasis on Alzheimer's disease
    Sjogren, M
    Blennow, K
    JOURNAL OF NEUROCHEMISTRY, 2002, 81 : 73 - 73
  • [26] Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
    Iqbal, K
    Flory, M
    Khatoon, S
    Soininen, H
    Pirttila, T
    Lehtovirta, M
    Alafuzoff, I
    Blennow, K
    Andreasen, N
    Vanmechelen, E
    Grundke-Iqbal, I
    ANNALS OF NEUROLOGY, 2005, 58 (05) : 748 - 757
  • [27] Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease
    Choe, LH
    Dutt, MJ
    Relkin, N
    Lee, KH
    ELECTROPHORESIS, 2002, 23 (14) : 2247 - 2251
  • [28] Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons
    Jansson, Deidre
    Wang, Marie
    Thomas, Ronald G.
    Erickson, Michelle A.
    Peskind, Elaine R.
    Li, Ge
    Iliff, Jeffrey
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 86 (02) : 813 - 826
  • [29] Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease
    Kramberger, Milica Gregoric
    Jelic, Vesna
    Kareholt, Ingemar
    Enache, Daniela
    Jonhagen, Maria Eriksdotter
    Winblad, Bengt
    Aarsland, Dag
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2012, 2 (01): : 48 - 56
  • [30] Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study
    Li, Qiong-Yao
    Hu, He-Ying
    Zhang, Gao-Wen
    Hu, Hao
    Ou, Ya-Nan
    Huang, Liang-Yu
    Wang, An-Yi
    Gao, Pei-Yang
    Ma, Li-Yun
    Tan, Lan
    Yu, Jin-Tai
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)